Resource Logo

ADCC against gp120 in HIV positive rapid progressors.


Natl Conf Hum Retroviruses Relat Infect (2nd). 1995 Jan 29-Feb 2;:87.

Participants in the Multicenter AIDS Cohort Study (MACS) who seroconverted during the study and progressed to AIDS within a three year period were evaluated to determine the titers of antibodies that could mediate antibody-dependent cell- mediated cytotoxicity (ADCC) against gp120. Effector cells from healthy donors were incubated with serum from MACS participants and CEM.NKR target cells that had been incubated with recombinant gp120. In previous studies serum samples from three time points were evaluated: the last seronegative visit, the first seropositive visit, and the last visit prior to the diagnosis of AIDS. Serum dilutions of 1/400, 1/2,000, and 1/10,000 were each assayed at three effector to target cell ratios and percent specific release values were converted to lytic units. ADCC activity was recorded as the highest serum dilution with maximum activity. Earlier results indicated that the titer declined or did not surpass 400 for 65% of the 17 rapid progressors evaluated. The goal of the current study was to determine whether rapid progressors with low or declining ADCC activity at the times previously evaluated ever had higher ADCC titers. Therefore, serum samples from intermediate time points were assayed. Results indicate that some individuals with low titers had rising levels of ADCC activity at intermediate time points and lost activity prior to the onset of AIDS. Additional time points from these 17 individuals are currently being evaluated. This indicates that a decline in ADCC titer may precede disease progression and that ADCC may be important in host defense.

Acquired Immunodeficiency Syndrome/*IMMUNOLOGY *Antibody-Dependent Cell Cytotoxicity Human HIV Envelope Protein gp120/*IMMUNOLOGY HIV Infections/IMMUNOLOGY/*PHYSIOPATHOLOGY Time Factors ABSTRACT


Information in this article was accurate in December 30, 1995. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.